J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI

Slides:



Advertisements
Similar presentations
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advertisements

Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Role of Nodal Irradiation in Breast Cancer
The PRIAS Study In Australia One Institution’s Experience Introduction PRIAS (Prostate cancer Research International: Active Surveillance – NTR1718) is.
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Joint Hospital Surgical Grand Round PYNEH, 18th April 2015
Clinical Utility of Combidex in Various Cancers
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Steven Joniau Filip Ameye
Role of Neck Dissection for Differentiated Thyroid CA Joint Hospital Surgical Grand Round NDH Dr. Alex TSANG.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Surgical Management of Urothelial Carcinoma A 21 st Century Approach Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Weill Medical College.
Prostate Cancer By: Kurt Rishel.
Howard M. Sandler, MD University of Michigan Medical School
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.
Prostate Cancer Treatment: What’s Best For You?
Prevention with Finasteride Ian M. Thompson, MD October, 2009.
TNM BLADDER CANCER STAGING Dr. Mahnaz Roayaei Radiation Oncologist Assistant Professor Isfahan University of Medical Sciences.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Lymphadenectomy in the surgical treatment of prostate cancer - does it influence survival? Oliver Hakenberg Urologische Klinik und Poliklinik Universitätsklinikum.
Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.
South West Public Health Observatory South West Regional Public Health Group Prostate cancer in England and the South West Sean McPhail 1, Paul Eves 1,
South West Public Health Observatory The changing casemix of prostate cancer patients and prostatectomies in the South West Sean McPhail.
Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
Journal Club August 10, 2012 Ryan M. Zitnay MD. Case 71 y/o male veteran w PMH CAD s/p MI, HTN, HL, constipation Followed by urology for rising PSA x.
Surgical Management of Prostate Cancer
Robotic-assisted Laparoscopic Prostatectomy
Per-Anders Abrahamsson Department of Urology Malmö University Hospital
Short-term outcome of neo-adjuvant chemotherapy
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Surgical Treatment in Locally Advanced Prostate Cancer
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital
Bladder Cancer and Prostatic Cancer
1 LINFOADENECTOMIA Alessandro Volpe Università del Piemonte Orientale
Basile Pache, Antonia Digklia*, Nicolas Demartines, Maurice Matter.
Post Op Positive Apex Margins Case 3: Prostate_3
Correlations between Urologic and Head and Neck Cancers
RELAZIONE TRA “STAGE MIGRATION” E
Prof. Shaila Anwar Professor Obs & Gynae
2017 USPSTF Draft Recommendations for Prostate Cancer Screening
Laparoscopic Radical prostatectomy: Is it still a treament of choice?
Prof.S.M.Haider Faisal Hameed Wahab Kadri
Prostate Cancer: Highlights from 2006
盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖
Jaden D. Evans, MD, Krishan R
ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE
Apollo Gleneagles Hospitals,
Dr T P E Wells 13 July 2018 Breast SSG Bath
Prostate Cancer Screening- Update
Volume 62, Issue 1, Pages (July 2012)
Active Surveillance for Low Risk Prostate Cancer
Stamatia Destounis, MD, FACR, FSBI, FAIUM
Prostate Cancer Update
Volume 54, Issue 2, Pages (August 2008)
A case of localized Prostate Cancer Marije Hamaker.
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.
Surgery for high-risk prostate cancer: The results of first 80 cases
Presentation transcript:

J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI The Role of Lynphadenectomy in the Treatment of Prostate Cancer XVI Workshop Urologic Oncology J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI

Introduction The pathways of Metastasis in PCA is not well understood. Is there a cascade of dissemination;to the L.N followed by Bone?Or is metastasis tumor dependent ie.Some tumors metastasizes via Lymphatic and other Hematogenous, or both ?

Lymphatic Metastasis in Radical Prostatectomy Specimens Since the introduction of PSA Screening the % of patients with L.N.+ has decreased from 10-20% in 1990 to <1% now. In view of this many authors have stopped doing L.N. dissections in patients with low risk disease.

Important questions for the Practicing Urologist Is it possible to detect L.N. Metastasis Pre Surgery? Is L.N. Dissection only of Staging Value? Is there a Therapeutic value? What is the Extend of L.N. Dissection?

Pre Operative Studies Pedal Lymphangiogram can Identify nodes in the area of Prostatic drainage . (Zoretic and Pontes) but is rarely used. CT Scan is unreliable for detecting L.N. Metastasis.The largest node was the site of N+ in 27% of cases while in 74% N+ where <1cm ( Cher et al. JU)

The case Against L.N. Dissection The low probability of N+ does not justify L.N.Dissection. The long term results of Perineal Prostatectomy for patients with localized PCA are comparable to RRP plus L.N. Dissection Significant Morbidity, specially when the Dissection is extended

The Case for L.N.Dissection Several recent Studies have shown the potential therapeutic benefit of L.N. Dissection. In a prospective randomized study 20% of patients with N+ in the observation arm where NED. If there is a benefit in L.N Dissection in a sub group of patients with Bladder Ca why not in PCA?

Relationship of PSA and N+. KCI / WSU Number:1,700 cases 1990-1995: 72 patients N+ Average PSA:32ng/ml 1996-2005: 30 patients N+ Average PSA:19ng/ml 2006-2007: 5 patients N+ Average PSA:10ng/ml

Case Report A 60 year old Chairman of a dept. at WSU/SOM, diagnosed wit PCA Gleason VII, underwent a RPP/LND showing M+, LN-. Post op PSA remained undetectable for 18 months, and developed progressive rise. Radiation therapy to the prostatic area decreased PSA to undetectable levels. One year later, a rise of PSA, led to an CT evaluation which detected a perirectal node. Excision led to an undetectable PSA for another 1 year.

Case Report Follow up and Conclusion One year later, a progressive elevation of PSA was observed. A CT of abdomen and pelvis, showed a single enlarged L.N. on the R iliac region, which had a previous negative dissection. Surgical excision of Node, led to an undetectable PSA, which has remained for the last 7 years!

Studies in L.N. Dissection Author Number L.N. % L.N.+ Ext. Limited Ext. Limited Golimbu 1987 43 21 ALL Stone 18 9 23% 7% Heidenreich 26% 12% Studer 2003 20 10 24%

CONCLUSIONS It appears that L.N Dissection can be curative in up to 20% of patients with N+ Extended L.N. Dissection remove 2 times as many nodes as Limited Dissection Presently there are no reliable pre op diagnostic tests to identify N+ Patients should be stratified pre operatively as to the need of extended Dissection.